Overview

A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargas

Status:
Terminated

Trial end date:
2016-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effectiveness,safety, and dosage of pegcrisantaspase in patients with Acute Lymphoblastic Leukemia (ALL) / Lymphoblastic Lymphoma (LBL).

Phase:

Phase 2

Details

Lead Sponsor:

Jazz Pharmaceuticals

Treatments:

Pegaspargase